Abstract
Mepolizumab has been shown to improve severe asthma control in clinical trials. However, physicians treat holistically and consider comorbid conditions when selecting therapy. Atopy, obesity, and depression/anxiety affect patients with asthma at an increased rate, yet few studies have examined asthma therapy with these comorbidities. This study examined the impact of mepolizumab in patients with severe asthma and atopy, obesity or depression/anxiety.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
